MedKoo Cat#: 130064 | Name: Zasocitinib
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zasocitinib, also commonly known as NDI-034858 and TAK-279, is an allosteric TYK2 inhibitor for anti-inflammatory applications. Phase 2b trials have been undergone for use of Zasocitinib as a treatment for moderate-to-severe plaque psoriasis in adults.

Chemical Structure

Zasocitinib
Zasocitinib
CAS#2272904-53-5

Theoretical Analysis

MedKoo Cat#: 130064

Name: Zasocitinib

CAS#: 2272904-53-5

Chemical Formula: C23H24N8O3

Exact Mass: 460.1971

Molecular Weight: 460.50

Elemental Analysis: C, 59.99; H, 5.25; N, 24.33; O, 10.42

Price and Availability

Size Price Availability Quantity
1mg USD 750.00 2 Weeks
5mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Zasocitinib; NDI-034858; NDI034858; NDI 034858; TAK-279; TAK 279; TAK279;
IUPAC/Chemical Name
N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo[1(2H),2'-bipyridin]-3-yl)amino]-pyrazolo[1,5-a]pyrimidine-3-carboxamide
InChi Key
BWINBHTTZLVXGT-NVXWUHKLSA-N
InChi Code
InChI=1S/C23H24N8O3/c1-24-20-12-18(27-16-6-5-11-30(23(16)33)19-7-3-4-10-25-19)29-21-14(13-26-31(20)21)22(32)28-15-8-9-17(15)34-2/h3-7,10-13,15,17,24H,8-9H2,1-2H3,(H,27,29)(H,28,32)/t15-,17-/m1/s1
SMILES Code
O=C(C1=C2N=C(NC3=CC=CN(C4=NC=CC=C4)C3=O)C=C(NC)N2N=C1)N[C@H]5[C@H](OC)CC5
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Cytokines, such as those in the interleukin (IL)-23/IL-17 axis, play an important role in the pathogenesis of psoriasis. Janus kinase, along with STAT, regulate intracellular signaling of key cytokines involved in the (IL)-23/IL-17 axis. TYK2 inhibition leads to the suppression of these signals.

Preparing Stock Solutions

The following data is based on the product molecular weight 460.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Loo WJ, Turchin I, Prajapati VH, Gooderham MJ, Grewal P, Hong CH, Sauder M, Vender RB, Maari C, Papp KA. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. J Cutan Med Surg. 2023 Jan-Feb;27(1_suppl):3S-24S. doi: 10.1177/12034754221141680. Epub 2022 Dec 15. PMID: 36519621. https://www.nimbustx.com/2022/11/30/nimbus-therapeutics-announces-positive-topline-results-for-phase-2b-clinical-trial-of-allosteric-tyk2-inhibitor-in-psoriasis/ https://clinicaltrials.gov/ct2/show/NCT04999839